Impact of Clinical Pharmacist Integration on Weight Management and Transplant Eligibility Among Patients With End‐Stage Kidney Disease With Obesity
- 11 November 2026
- journal article
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (12)
Abstract
Background: Obesity is a barrier to kidney transplantation in patients with end‐stage kidney disease (ESKD). Injectable incretin peptides (IIP) have transformed weight management; however, real‐world data in ESKD are limited. This study evaluated the impact of integrating a clinical pharmacist practitioner (CPP) into an interprofessional high body mass index (BMI) kidney transplant clinic on weight loss and transplant eligibility outcomes. Methods: This single‐center, retrospective study included adults with ESKD and obesity‐prescribed IIP for transplant eligibility between June, 2022 and December, 2024. Cohort 1 included patients treated before CPP implementation; Cohort 2 included patients following implementation. The primary outcome was the percent change in body mass index (BMI) at 3, 6, and 12 months following IIP initiation. Secondary outcomes included changes in transplant eligibility status, IIP dose intensity, and predefined adverse events (AEs) at 12 months. Results: Eighty‐four patients were included (Cohort 1: n = 28; Cohort 2: n = 56). Cohort 2 achieved greater BMI reductions at 3 (−2.0% vs. +1.45%), 6 (−3.3% vs. +1.16%), and 12 months (−8.0% vs. +2.8%; p < 0.01 for all). Among patients initially ineligible for kidney transplantation, 45% of patients in Cohort 2 became active on the transplant waitlist by 12 months compared with 11.5% in Cohort 1 ( p = 0.006). More patients in Cohort 2 reached high IIP dose intensity (48.2% vs. 3.6%, p < 0.001), without differences in AE. Conclusions: IIP therapy appears safe and effective in ESKD. CPP integration was associated with greater weight loss, increased achievement of active transplant eligibility, and improved treatment optimization, highlighting its potential role in addressing obesity‐related barriers to transplantation.This publication has 11 references indexed in Scilit:
- The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medicationsJournal of Clinical Investigation, 2026
- The use of GLP-1 agonists in patients with end-stage kidney disease in an urban underserved patient populationThe American Journal of the Medical Sciences, 2026
- Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled TrialsDiabetes Care, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine, 2022
- Management of obesity in kidney transplant candidates and recipients: A clinical practice guideline by the DESCARTES Working Group of ERANephrology Dialysis Transplantation, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney TransplantationTransplantation, 2020
- Differential Association of Body Mass Index with Access to Kidney Transplantation in Men and WomenClinical Journal of the American Society of Nephrology, 2014
- US Pharmacists' Effect as Team Members on Patient CareMedical Care, 2010